Cargando…
Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis
OBJECTIVE: Preclinical and clinical studies suggest that activation of the µ-opioid receptor may reduce overall survival and increase the risk for all-cause mortality in patients with cancer and noncancer pain. Methylnaltrexone, a selective, peripherally acting µ-opioid receptor antagonist, has demo...
Autores principales: | Webster, Lynn R, Brenner, Darren, Israel, Robert J, Stambler, Nancy, Slatkin, Neal E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977130/ https://www.ncbi.nlm.nih.gov/pubmed/36102822 http://dx.doi.org/10.1093/pm/pnac136 |
Ejemplares similares
-
The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021) -
Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018) -
Correction to: The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021) -
Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials
por: Mehta, Neel, et al.
Publicado: (2023) -
Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose
por: Chamberlain, Bruce H, et al.
Publicado: (2023)